Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.61 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.59 |
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | RARA | P10276 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RARG | P13631 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 6/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10796899 | 0.85 | KAT8 (0.58) | RARBKAT8PPARAPPARGRARA | |
| SCHEMBL5609669 | 0.84 | RARB (0.78) | RARBKAT8PPARAPPARGRARA | |
| SCHEMBL20503376 | 0.84 | RARB (0.78) | RARBKAT8PPARAPPARGRARA | |
| SCHEMBL4308582 | 0.84 | RARB (0.78) | RARBKAT8PPARAPPARGRARA | |
| SCHEMBL11028587 | 0.84 | RARB (0.78) | RARBKAT8PPARAPPARGRARA | |
| SCHEMBL2403600 | 0.82 | GRIN2D (0.67) | RARBKAT8PPARARARAMEN1 | |
| SCHEMBL7342564 | 0.82 | GRIN2D (0.67) | RARBKAT8PPARARARAMEN1 | |
| SCHEMBL7331987 | 0.82 | GRIN2D (0.67) | RARBKAT8PPARARARAMEN1 | |
| SCHEMBL8303752 | 0.82 | GRIN2D (0.67) | RARBKAT8PPARARARAMEN1 | |
| Hydrochloric Acid SCHEMBL10716592 | 0.81 | GRIN2D (0.65) | RARBKAT8PPARARARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | RARB 1554/4885KAT8 4090/4885PPARA 3021/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | RARB 1554/4885KAT8 4090/4885PPARA 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.